Cingulate (CING) news
Recent news
Cingulate Inc: Ascendant Capital Markets cuts target price to $44 from $52
Ascendiant Capital has revised its price target for Cingulate Inc. (NASDAQ:CING), lowering it to $44 from a previous $52, while maintaining a "Buy" rating on the stock. The updated target reflects a reassessment of the company’s valuation, balancing the inherent risks of its development-stage…
AInvest Wire · Aug 20, 2026Cingulate: cash & cash equivalents provide runway thru mid-2027
Cingulate Inc. (NASDAQ: CING) reported a net loss of $9.3 million for the first quarter ended March 31, 2026, compared to a loss of $3.9 million in the same period in 2025. Despite the increased loss, the company’s cash and cash equivalents rose to $25.9 million as of March 31, 2026, up from $10.95…
AInvest Wire · Aug 13, 2026Cingulate to resubmit NDA to FDA as promptly as practicable
AInvest Wire · Aug 13, 2026Cingulate has nearly $30 mln in cash reserves to fund operations into 2027
AInvest Wire · Jun 2, 2026Cingulate receives complete response letter from FDA for CTX-1301
Cingulate Inc. (NASDAQ: CING) recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for CTx-1301, a once-daily ADHD treatment . The CRL indicates that the application cannot be approved in its current form and outlines…
AInvest Wire · Jun 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.